Romain Siegrist

Allschwil, BL 4123, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Discovery and In-Vivo Characterization of Kv7 Channel Openers through a Phenotypic Approach.

Discovery and In-Vivo Characterization of Kv7 Channel Openers through a Phenotypic Approach.

Journal: Journal of medicinal chemistry

Published: August 12, 2025

Discovery of a New Class of Orexin 2 Receptor Agonists as a Potential Treatment for Narcolepsy.

Discovery of a New Class of Orexin 2 Receptor Agonists as a Potential Treatment for Narcolepsy.

Journal: Journal of medicinal chemistry

Published: May 05, 2025

IDOR-1104-0086, a novel Kv7 channel activator with antiseizure effects in rodents.

IDOR-1104-0086, a novel Kv7 channel activator with antiseizure effects in rodents.

Journal: Neuropharmacology

Published: April 26, 2025

Design, Synthesis, and Optimization of Indole Acetic Acid Derivatives as Potent and Selective CRTH2 Receptor Antagonists: Discovery of ACT-774312.

Design, Synthesis, and Optimization of Indole Acetic Acid Derivatives as Potent and Selective CRTH2 Receptor Antagonists: Discovery of ACT-774312.

Journal: ChemMedChem

Published: January 06, 2023

Discovery of a Potent, Selective T-type Calcium Channel Blocker as a Drug Candidate for the Treatment of Generalized Epilepsies.

Discovery of a Potent, Selective T-type Calcium Channel Blocker as a Drug Candidate for the Treatment of Generalized Epilepsies.

Journal: Journal of medicinal chemistry

Published: November 09, 2017

Milestones to the Discovery of T-type Calcium Channel Blockers for the Treatment of Generalized Epilepsies.

Milestones to the Discovery of T-type Calcium Channel Blockers for the Treatment of Generalized Epilepsies.

Journal: Chimia

Published: October 27, 2017

The Screening Compound Collection: A Key Asset for Drug Discovery.

The Screening Compound Collection: A Key Asset for Drug Discovery.

Journal: Chimia

Published: October 27, 2017

Correction to Structure-Activity Relationship, Drug Metabolism and Pharmacokinetics Properties Optimization, and in Vivo Studies of New Brain Penetrant Triple T-Type Calcium Channel Blockers.

Correction to Structure-Activity Relationship, Drug Metabolism and Pharmacokinetics Properties Optimization, and in Vivo Studies of New Brain Penetrant Triple T-Type Calcium Channel Blockers.

Journal: Journal of medicinal chemistry

Published: February 25, 2017

Structure-Activity Relationship, Drug Metabolism and Pharmacokinetics Properties Optimization, and in Vivo Studies of New Brain Penetrant Triple T-Type Calcium Channel Blockers.

Structure-Activity Relationship, Drug Metabolism and Pharmacokinetics Properties Optimization, and in Vivo Studies of New Brain Penetrant Triple T-Type Calcium Channel Blockers.

Journal: Journal of medicinal chemistry

Published: December 10, 2016

Discovery and Characterization of ACT-451840: an Antimalarial Drug with a Novel Mechanism of Action.

Discovery and Characterization of ACT-451840: an Antimalarial Drug with a Novel Mechanism of Action.

Journal: ChemMedChem

Published: June 13, 2016

Substituted pyrrolidin-2-ones: Centrally acting orexin receptor antagonists promoting sleep. Part 2.

Substituted pyrrolidin-2-ones: Centrally acting orexin receptor antagonists promoting sleep. Part 2.

Journal: Bioorganic & medicinal chemistry letters

Published: February 20, 2015

Structure-activity relationship, biological, and pharmacological characterization of the proline sulfonamide ACT-462206: a potent, brain-penetrant dual orexin 1/orexin 2 receptor antagonist.

Structure-activity relationship, biological, and pharmacological characterization of the proline sulfonamide ACT-462206: a potent, brain-penetrant dual orexin 1/orexin 2 receptor antagonist.

Journal: ChemMedChem

Published: June 23, 2014

Showing 1-12 of 16

Last Updated: 09/26/2026